Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
Sato T, Yamauchi J, Yagishita N, Araya N, Takao N, Ohta Y, Inoue E, Takahashi M, Yamagishi M, Suzuki Y, Uchimaru K, Matsumoto N, Hasegawa Y, Yamano Y.
Sato T, et al. Among authors: inoue e.
Brain. 2023 Aug 1;146(8):3181-3191. doi: 10.1093/brain/awad139.
Brain. 2023.
PMID: 37093965